10 Metric Ton	FOB Price: USD 8500.0000

Min.Order :10 Metric Ton
Purity: 97%
Payment Terms : L/C,T/T,Other

Keywords

865363-93-5 EFDA Wholesaler EFDA supplier 865363-93-5 EFDA

Quick Details

Appearance:White powder
Application:CAS#865363-93-5;Pharmaceutical intermediates;API;R&D use only
PackAge:According to customer
ProductionCapacity:1|Kilogram|Month
Storage:Store in a tightly closed container, in a cool and dry place.
Transportation:Fedex,DHL,TNT,BY SEA and BY AIR

Superiority:

Islatravir (4′-ethynyl-2-fluoro-2′-deoxyadenosine, EFdA, or MK-8591) is an investigational drug for the treatment of HIV infection.

It is classified as a nucleoside reverse transcriptase translocation inhibitor (NRTTI). Merck is developing a subdermal drug-eluting implant to administer islatravir.

Biological activity

Islatravir has activity against HIV in animal models, and is being studied clinically for HIV treatment and prophylaxis. Islatravir is a nucleoside analog reverse transcriptase translocation inhibitor that unlike other such inhibitors, inhibits HIV through multiple mechanisms, providing rapid suppression of the virus, when tested in macaques and mice.Nevertheless, there are HIV strains resistant to islatravir and research is ongoing.

Wholesaler supplier 865363-93-5 EFDA

Details:

Islatravir (4′-ethynyl-2-fluoro-2′-deoxyadenosine, EFdA, or MK-8591) is an investigational drug for the treatment of HIV infection.

It is classified as a nucleoside reverse transcriptase translocation inhibitor (NRTTI). Merck is developing a subdermal drug-eluting implant to administer islatravir.

Biological activity

Islatravir has activity against HIV in animal models, and is being studied clinically for HIV treatment and prophylaxis. Islatravir is a nucleoside analog reverse transcriptase translocation inhibitor that unlike other such inhibitors, inhibits HIV through multiple mechanisms, providing rapid suppression of the virus, when tested in macaques and mice.Nevertheless, there are HIV strains resistant to islatravir and research is ongoing.